While Sanofi's antacid medicine Zantac (ranitidine) and its generic versions face immediate withdrawal in the US due to nitrosamine impurities, the European Medicines Agency is continuing to conduct its own review of ranitidine-containing medicines and “will formulate an opinion in due course.”
The next discussion on the safety of ranitidine medicines is foreseen later this month when the EMA’s human medicines evaluation...